PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21162905-15 2010 CONCLUSIONS: In our experiment, SST decreases the expression of MDR1 mRNA and P-gp protein so as to reduce the efflux of DOX and elevate DOX concentrations in GBC-SD cells. Doxorubicin 121-124 somatostatin Homo sapiens 32-35 21162905-0 2010 [Somatostatin enhanced anti-tumor effect of doxorubicin on gallbladder cancer cells through the regulation of intracellular drug concentration]. Doxorubicin 44-55 somatostatin Homo sapiens 1-13 21162905-1 2010 OBJECTIVE: To investigate the possible mechanisms by which Somatostatin (SST) enhances the anti-tumor effect of doxorubicin (DOX) on gallbladder cancer cells. Doxorubicin 112-123 somatostatin Homo sapiens 59-71 21162905-15 2010 CONCLUSIONS: In our experiment, SST decreases the expression of MDR1 mRNA and P-gp protein so as to reduce the efflux of DOX and elevate DOX concentrations in GBC-SD cells. Doxorubicin 137-140 somatostatin Homo sapiens 32-35 21162905-1 2010 OBJECTIVE: To investigate the possible mechanisms by which Somatostatin (SST) enhances the anti-tumor effect of doxorubicin (DOX) on gallbladder cancer cells. Doxorubicin 112-123 somatostatin Homo sapiens 73-76 21162905-1 2010 OBJECTIVE: To investigate the possible mechanisms by which Somatostatin (SST) enhances the anti-tumor effect of doxorubicin (DOX) on gallbladder cancer cells. Doxorubicin 125-128 somatostatin Homo sapiens 59-71 21162905-1 2010 OBJECTIVE: To investigate the possible mechanisms by which Somatostatin (SST) enhances the anti-tumor effect of doxorubicin (DOX) on gallbladder cancer cells. Doxorubicin 125-128 somatostatin Homo sapiens 73-76 21162905-11 2010 Interestingly, at Hour 24 post-treatment, SST+DOX group showed more robust inhibitory effect on GBC-SD cells as compared to DOX alone group. Doxorubicin 124-127 somatostatin Homo sapiens 42-45 21162905-13 2010 SST could increase intracellular DOX concentration. Doxorubicin 33-36 somatostatin Homo sapiens 0-3 21162905-14 2010 And the difference of intracellular DOX concentration between SST+DOX group and DOX group at Hour 24 was statistically significant. Doxorubicin 36-39 somatostatin Homo sapiens 62-65 20359855-0 2010 The mechanisms of somatostatin induced enhanced chemosensitivity of gallbladder cancer cell line to doxorubicin: cell cycle modulation plus target enzyme up-regulation. Doxorubicin 100-111 somatostatin Homo sapiens 18-30 20359855-3 2010 We have illustrated that somatostatin (SST) can enhance chemosensitivity of gallbladder cancer to Doxorubicin (DOX) in our precious studies. Doxorubicin 98-109 somatostatin Homo sapiens 25-37 20359855-3 2010 We have illustrated that somatostatin (SST) can enhance chemosensitivity of gallbladder cancer to Doxorubicin (DOX) in our precious studies. Doxorubicin 98-109 somatostatin Homo sapiens 39-42 20359855-3 2010 We have illustrated that somatostatin (SST) can enhance chemosensitivity of gallbladder cancer to Doxorubicin (DOX) in our precious studies. Doxorubicin 111-114 somatostatin Homo sapiens 25-37 20359855-3 2010 We have illustrated that somatostatin (SST) can enhance chemosensitivity of gallbladder cancer to Doxorubicin (DOX) in our precious studies. Doxorubicin 111-114 somatostatin Homo sapiens 39-42 20359855-4 2010 Here, we explored the possible mechanisms by which SST used to enhance the cytotoxicity of DOX on gallbladder carcinoma cell line. Doxorubicin 91-94 somatostatin Homo sapiens 51-54 20359855-12 2010 After 24h treatment with SST and DOX, apoptosis index significantly increased than that of DOX alone (P<0.05). Doxorubicin 91-94 somatostatin Homo sapiens 25-28 20359855-15 2010 CONCLUSION: These results suggested that SST could induce cell cycle block in S phase in GBC-SD cells line, the most sensitive phase of the cell cycle for DOX, through up-regulating Rb, E2F-1 and ICBP90 protein expression. Doxorubicin 155-158 somatostatin Homo sapiens 41-44 20359855-17 2010 We concluded that the mechanisms of SST enhanced chemosensitivity of GBC-SD cell line to DOX might be cell cycle arrest plus up-regulated target enzyme. Doxorubicin 89-92 somatostatin Homo sapiens 36-39 25961976-7 2010 We have developed a series of cytotoxic peptides based on doxorubicin or its derivative 2-pyrrolino-doxorubicin coupled to an analog of LH-RH, somatostatin or bombesin. Doxorubicin 58-69 somatostatin Homo sapiens 143-155 19491659-1 2009 In view of findings that various tumors express receptors for somatostatin, a new targeted cytotoxic analog of somatostatin, AN-162 (AEZS-124), consisting of doxorubicin linked through glutaric acid to the somatostatin octapeptide RC-121 was developed in our laboratory. Doxorubicin 158-169 somatostatin Homo sapiens 62-74 19491659-1 2009 In view of findings that various tumors express receptors for somatostatin, a new targeted cytotoxic analog of somatostatin, AN-162 (AEZS-124), consisting of doxorubicin linked through glutaric acid to the somatostatin octapeptide RC-121 was developed in our laboratory. Doxorubicin 158-169 somatostatin Homo sapiens 111-123 19491659-1 2009 In view of findings that various tumors express receptors for somatostatin, a new targeted cytotoxic analog of somatostatin, AN-162 (AEZS-124), consisting of doxorubicin linked through glutaric acid to the somatostatin octapeptide RC-121 was developed in our laboratory. Doxorubicin 158-169 somatostatin Homo sapiens 111-123 16047355-3 2005 The cytotoxic somatostatin (SST) analog, AN-238, consists of a superactive derivative of doxorubicin (DOX), 2-pyrrolino-DOX (AN-201), linked to the SST analog carrier, RC-121. Doxorubicin 89-100 somatostatin Homo sapiens 14-26 16047355-3 2005 The cytotoxic somatostatin (SST) analog, AN-238, consists of a superactive derivative of doxorubicin (DOX), 2-pyrrolino-DOX (AN-201), linked to the SST analog carrier, RC-121. Doxorubicin 89-100 somatostatin Homo sapiens 28-31 16047355-3 2005 The cytotoxic somatostatin (SST) analog, AN-238, consists of a superactive derivative of doxorubicin (DOX), 2-pyrrolino-DOX (AN-201), linked to the SST analog carrier, RC-121. Doxorubicin 89-100 somatostatin Homo sapiens 148-151 16047355-3 2005 The cytotoxic somatostatin (SST) analog, AN-238, consists of a superactive derivative of doxorubicin (DOX), 2-pyrrolino-DOX (AN-201), linked to the SST analog carrier, RC-121. Doxorubicin 102-105 somatostatin Homo sapiens 14-26 16047355-3 2005 The cytotoxic somatostatin (SST) analog, AN-238, consists of a superactive derivative of doxorubicin (DOX), 2-pyrrolino-DOX (AN-201), linked to the SST analog carrier, RC-121. Doxorubicin 102-105 somatostatin Homo sapiens 28-31 16047355-3 2005 The cytotoxic somatostatin (SST) analog, AN-238, consists of a superactive derivative of doxorubicin (DOX), 2-pyrrolino-DOX (AN-201), linked to the SST analog carrier, RC-121. Doxorubicin 102-105 somatostatin Homo sapiens 148-151 11290438-1 2001 Recently, we developed a cytotoxic analogue of somatostatin (SST), AN-238, in which the SST carrier peptide RC-121 was linked to 2-pyrrolinodoxorubicin (2-pyrrolino-DOX) (AN-201), a potent derivative of doxorubicin. Doxorubicin 140-151 somatostatin Homo sapiens 47-59 11290438-1 2001 Recently, we developed a cytotoxic analogue of somatostatin (SST), AN-238, in which the SST carrier peptide RC-121 was linked to 2-pyrrolinodoxorubicin (2-pyrrolino-DOX) (AN-201), a potent derivative of doxorubicin. Doxorubicin 140-151 somatostatin Homo sapiens 61-64 11290438-1 2001 Recently, we developed a cytotoxic analogue of somatostatin (SST), AN-238, in which the SST carrier peptide RC-121 was linked to 2-pyrrolinodoxorubicin (2-pyrrolino-DOX) (AN-201), a potent derivative of doxorubicin. Doxorubicin 140-151 somatostatin Homo sapiens 88-91 10690557-2 2000 This study was conducted to investigate the effects of targeted cytotoxic SST analogue AN-238, consisting of 2-pyrrolinodoxorubicin (AN-201), a potent derivative of doxorubicin (DOX) linked to somatostatin analogue RC-121, on the growth of SST receptor-positive U-87 MG human glioblastomas. Doxorubicin 120-131 somatostatin Homo sapiens 74-77 10690557-2 2000 This study was conducted to investigate the effects of targeted cytotoxic SST analogue AN-238, consisting of 2-pyrrolinodoxorubicin (AN-201), a potent derivative of doxorubicin (DOX) linked to somatostatin analogue RC-121, on the growth of SST receptor-positive U-87 MG human glioblastomas. Doxorubicin 120-131 somatostatin Homo sapiens 193-205 10690557-2 2000 This study was conducted to investigate the effects of targeted cytotoxic SST analogue AN-238, consisting of 2-pyrrolinodoxorubicin (AN-201), a potent derivative of doxorubicin (DOX) linked to somatostatin analogue RC-121, on the growth of SST receptor-positive U-87 MG human glioblastomas. Doxorubicin 178-181 somatostatin Homo sapiens 74-77 10690557-2 2000 This study was conducted to investigate the effects of targeted cytotoxic SST analogue AN-238, consisting of 2-pyrrolinodoxorubicin (AN-201), a potent derivative of doxorubicin (DOX) linked to somatostatin analogue RC-121, on the growth of SST receptor-positive U-87 MG human glioblastomas. Doxorubicin 178-181 somatostatin Homo sapiens 193-205 20156671-0 2010 Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells. Doxorubicin 117-128 somatostatin Homo sapiens 19-31 20156671-1 2010 The effect of the targeted cytotoxic somatostatin (SST) analog AN-162, consisting of doxorubicin (DOX) conjugated to SST carrier RC-121, was investigated on the growth of human colorectal cancer (CRC) cell lines HT-29, HCT-15, and HCT-116 and a DOX-resistant mouse leukemia cell line P388/R84. Doxorubicin 85-96 somatostatin Homo sapiens 37-49 9465096-0 1998 Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Doxorubicin 84-95 somatostatin Homo sapiens 60-72